Connection

Jean-Charles Soria to Adult

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Adult.
Jean-Charles Soria
Connection Strength
0.240
Adult
  1. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 09; 101:201-209.
    View in: PubMed
    Score: 0.013
  2. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 01 11; 378(2):113-125.
    View in: PubMed
    Score: 0.012
  3. Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. Invest New Drugs. 2018 08; 36(4):619-628.
    View in: PubMed
    Score: 0.012
  4. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. Eur J Cancer. 2017 11; 86:186-196.
    View in: PubMed
    Score: 0.012
  5. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. Eur J Cancer. 2017 08; 81:142-150.
    View in: PubMed
    Score: 0.012
  6. RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. Eur J Cancer. 2017 09; 83:185-193.
    View in: PubMed
    Score: 0.012
  7. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 01; 35(22):2535-2541.
    View in: PubMed
    Score: 0.012
  8. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017 Jun 06; 116(12):1505-1512.
    View in: PubMed
    Score: 0.012
  9. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017 06; 7(6):586-595.
    View in: PubMed
    Score: 0.012
  10. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 03 04; 389(10072):917-929.
    View in: PubMed
    Score: 0.012
  11. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer. 2011 Oct; 47(15):2249-55.
    View in: PubMed
    Score: 0.008
  12. DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. Am J Clin Oncol. 2010 Aug; 33(4):341-5.
    View in: PubMed
    Score: 0.007
  13. Expression of cell cycle biomarkers and telomere length in papillary thyroid carcinoma: a comparative study between radiation-associated and spontaneous cancers. Am J Clin Oncol. 2009 Feb; 32(1):1-8.
    View in: PubMed
    Score: 0.007
  14. QTc monitoring during a phase I study: experience with SR271425. Am J Clin Oncol. 2007 Apr; 30(2):106-12.
    View in: PubMed
    Score: 0.006
  15. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death Differ. 2021 12; 28(12):3297-3315.
    View in: PubMed
    Score: 0.004
  16. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. Eur J Cancer. 2019 03; 109:103-110.
    View in: PubMed
    Score: 0.003
  17. Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clin Cancer Res. 2019 02 01; 25(3):946-956.
    View in: PubMed
    Score: 0.003
  18. Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 10 20; 36(30):2995-3006.
    View in: PubMed
    Score: 0.003
  19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018 09; 19(9):1180-1191.
    View in: PubMed
    Score: 0.003
  20. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer. 2018 09; 101:160-164.
    View in: PubMed
    Score: 0.003
  21. Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. Eur J Cancer. 2018 07; 98:17-22.
    View in: PubMed
    Score: 0.003
  22. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. J Clin Oncol. 2018 10 20; 36(30):3007-3014.
    View in: PubMed
    Score: 0.003
  23. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. Eur J Cancer. 2018 05; 95:68-74.
    View in: PubMed
    Score: 0.003
  24. Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors. Arch Cardiovasc Dis. 2018 Apr; 111(4):285-296.
    View in: PubMed
    Score: 0.003
  25. Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers? Eur J Cancer. 2018 05; 94:61-69.
    View in: PubMed
    Score: 0.003
  26. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018 Mar 01; 4(3):351-357.
    View in: PubMed
    Score: 0.003
  27. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. Eur J Cancer. 2018 03; 92:1-10.
    View in: PubMed
    Score: 0.003
  28. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. Br J Cancer. 2018 02 06; 118(3):344-352.
    View in: PubMed
    Score: 0.003
  29. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018 03; 91:21-29.
    View in: PubMed
    Score: 0.003
  30. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018 01; 88:38-47.
    View in: PubMed
    Score: 0.003
  31. Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017 12; 87:122-130.
    View in: PubMed
    Score: 0.003
  32. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? Eur J Cancer. 2017 12; 87:65-74.
    View in: PubMed
    Score: 0.003
  33. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017 10; 84:212-218.
    View in: PubMed
    Score: 0.003
  34. Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clin Cancer Res. 2017 Nov 01; 23(21):6411-6420.
    View in: PubMed
    Score: 0.003
  35. Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 2017 10; 112:10-15.
    View in: PubMed
    Score: 0.003
  36. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. Eur J Cancer. 2017 09; 83:194-202.
    View in: PubMed
    Score: 0.003
  37. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clin Cancer Res. 2017 Oct 15; 23(20):6101-6112.
    View in: PubMed
    Score: 0.003
  38. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017 09; 82:34-44.
    View in: PubMed
    Score: 0.003
  39. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. Eur J Cancer. 2017 08; 81:81-89.
    View in: PubMed
    Score: 0.003
  40. Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Invest New Drugs. 2018 02; 36(1):62-74.
    View in: PubMed
    Score: 0.003
  41. Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs. 2017 06; 28(5):540-545.
    View in: PubMed
    Score: 0.003
  42. Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. Cancer Res. 2017 05 01; 77(9):2222-2230.
    View in: PubMed
    Score: 0.003
  43. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 02; 387(10026):1415-1426.
    View in: PubMed
    Score: 0.003
  44. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer. 2004 Mar 22; 90(6):1222-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.